Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Lyell Immunopharma (LYEL) Shares Outstanding (Diluted Average) (2019 - 2025)

Lyell Immunopharma's Shares Outstanding (Diluted Average) history spans 7 years, with the latest figure at $16.0 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Diluted Average) rose 24.96% year-over-year to $16.0 million; the TTM value through Sep 2025 reached $16.0 million, up 24.96%, while the annual FY2024 figure was $261.5 million, 4.18% up from the prior year.
  • Shares Outstanding (Diluted Average) for Q3 2025 was $16.0 million at Lyell Immunopharma, up from $14.8 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $295.1 million in Q1 2025 and bottomed at $12.7 million in Q2 2024.
  • The 5-year median for Shares Outstanding (Diluted Average) is $245.3 million (2022), against an average of $172.4 million.
  • The largest annual shift saw Shares Outstanding (Diluted Average) soared 1313.72% in 2022 before it tumbled 94.9% in 2024.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $135.9 million in 2021, then surged by 81.79% to $247.1 million in 2022, then rose by 1.58% to $251.0 million in 2023, then rose by 4.18% to $261.5 million in 2024, then crashed by 93.9% to $16.0 million in 2025.
  • Per Business Quant, the three most recent readings for LYEL's Shares Outstanding (Diluted Average) are $16.0 million (Q3 2025), $14.8 million (Q2 2025), and $295.1 million (Q1 2025).